Migraine headache is a disabling condition that one in six Americans experience. Although many interventions for migraine prevention have shown to be effective, decision making for patients and physicians can be complex. Most pharmacologic therapies commonly used for migraine prevention were originally developed for treatment of other medical conditions such as hypertension, epilepsy, or depression. This project assesses the efficacy, tolerability, and side effects of traditional therapies for migraine prevention alongside newer therapies to inform decisions and identify evidence gaps.

This evidence visualization and corresponding report summarize the findings from a systematic rapid review of all randomized controlled trials of drugs and devices used for migraine prevention. Overall, 203 trials are represented in three interactive evidence visualizations:

• Map 1: Assesses effectiveness of 15 drugs and 2 devices for migraine reduction, tolerability, and reported harms from 78 placebo or sham-controlled trials.
• Map 2: Visualizes existing studies of placebo or sham-controlled randomized clinical trials drugs and devices for migraine prevention.
• Map 3: Visualizes existing studies of head-to-head comparative randomized clinical trials on drugs and devices for migraine prevention.